The Library
Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy
Tools
Song, Hualong, Zhou, Shanshan, Wang, Rubing and Li, Shaoshun (2013) Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy. ChemMedChem, Volume 8 (Number 11). pp. 1736-1749. doi:10.1002/cmdc.201300228 ISSN 1860-7179.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1002/cmdc.201300228
Abstract
A diverse group of proteins, the activities of which are precisely orchestrated during mitosis, have emerged as targets for cancer therapeutics; these include the Aurora kinases (AKs), Polo‐like kinases (PLKs), and the kinesin spindle protein (KSP). KSP is essential for the proper separation of spindle poles during mitosis. Agents that target KSP selectively act on cells undergoing cell division, which means that KSP inhibitors are mitosis‐specific drugs, and have demonstrated remarkable activities in vitro. However, a significant obstacle to the success of KSP inhibitors is that these compounds, with tremendous efficacy in vitro, have demonstrated little or even no antitumor activity in vivo. Accumulated data suggest that a combination of KSP inhibitors with various cytostatic drugs will result in a more powerful tumor‐killing effect than monotherapy. Combination therapies might predominate and represent the next frontier in the discovery research of KSP inhibitors as potential anticancer drugs. Few published studies have reviewed combination therapy using KSP inhibitors. Herein we provide a comprehensive review of the literature on KSP inhibitor monotherapy and therapeutic combinations. The current state and problems are also discussed.
Two are better than one: Targeted therapies in the form of antibodies and small molecules have been studied in combination with kinesin spindle protein (KSP) inhibitors to enhance their efficacy against cancer in preclinical investigations. Accumulated data suggest that a combination of KSP inhibitors with various cytostatic drugs will result in a more powerful tumor‐killing effect than monotherapy. Combination therapies may predominate and represent the next frontier in discovery research for KSP inhibitors as potential anticancer drugs.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Science > Chemistry | ||||
Journal or Publication Title: | ChemMedChem | ||||
Publisher: | Wiley - V C H Verlag GmbH & Co. KGaA | ||||
ISSN: | 1860-7179 | ||||
Official Date: | 2013 | ||||
Dates: |
|
||||
Volume: | Volume 8 | ||||
Number: | Number 11 | ||||
Page Range: | pp. 1736-1749 | ||||
DOI: | 10.1002/cmdc.201300228 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |